SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Amendment #4 Under the Securities and Exchange Act of 1934

Eiger BioPharmaceuticals, Inc.

(Name of Issuer)

Common Stock (Title of Class of Securities)

> 28249U105 (CUSIP Number)

December 31,2022 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

This Schedule is filed pursuant to Rule 13d-1(b)

The information required in the remainder of this cover page (except any items to which the form provides a cross-reference) shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

CUSIP NO. 28249U105

<u>.</u>						
1)	Name of Reporting Person		ng Person	Ameriprise Financial, Inc.		
	SS or IRS	S. Ide	ntification No. of Above Person	IRS No. 13-3180631		
2) Check the Appropriate Box if a Member of a Group						
_/						
		(b) [⊠*			
3)	SEC Use Only					
4)	Citizenship	or Pl	ace of Organization			
	Delaware	5)	Sole Voting Power			
		5)	Sole voting Power			
NI	JMBER OF		0			
	SHARES	6)	Shared Voting Power			
	NEFICIALLY					
0	WNED BY EACH	7)	4,744,649 Sole Dispositive Power			
RE	EPORTING	/)	Sole Dispositive Power			
]	PERSON		0			
	WITH	8)	Shared Dispositive Power			
			5 444 750			
9)			5,444,756 Int Beneficially Owned by Each Reporting	Derson		
,,	Aggregate 1	inot	int beneficiary owned by Each Reporting	1 (150)		
	5,444,756					
10)						
	Net Assult of L					
11)	Not Applicable) Percent of Class Represented by Amount In Row (9)					
		1455	represented by random in Row (5)			
12.35%						
12) Type of Reporting Person						
	HC					

* This filing describes the reporting person's relationship with other persons, but the reporting person does not affirm the existence of a group.

CUSIP NO. 28249U105

. <u> </u>						
1)	Name of Reporting Person		ng Person	Columbia Management Investment Advisers, LLC		
	SS or IRS	S Ide	ntification No. of Above Person	IRS No. 41-1533211		
2)						
3)	(a) \Box (b) \boxtimes^*					
5)	SEC Use Only					
4)	Citizenship or Place of Organization					
	Minnesota	5)	Sole Voting Power			
		5)	Sole voting rower			
NU	JMBER OF		0			
	SHARES	6)	Shared Voting Power			
	BENEFICIALLY OWNED BY EACH		4,744,649			
			Sole Dispositive Power			
	EPORTING PERSON		0			
1	WITH		0 Shared Dispositive Power			
		8)	Shared Dispositive Fower			
			5,442,206			
9)	Aggregate A	Amou	nt Beneficially Owned by Each Reportir	ng Person		
	5,442,206					
10)						
11)	Not Applicable 11) Percent of Class Represented by Amount In Row (9)					
11) Percent of Class Represented by Amount In Row (9)						
	12.35%					
12) Type of Reporting Person						
	ΙΑ					
L						

* This filing describes the reporting person's relationship with other persons, but the reporting person does not affirm the existence of a group.

CUSIP NO. 28249U105

1)	Name of Reporting Person		ng Person	Columbia Seligman Technology and Information Fund			
	S.S. or I.R.S	S. Ide	ntification No. of Above Person	IRS No. 13-3154450			
2)	Check the A						
	(a) \Box (b) \boxtimes^*						
3)							
4)							
4)	4) Citizenship or Place of Organization						
	Massachuse						
		5)	Sole Voting Power				
NU	JMBER OF		2,319,150				
5	SHARES	6)	Shared Voting Power				
	EFICIALLY WNED BY		0				
рг	EACH EPORTING	7)	Sole Dispositive Power				
	PERSON		0				
	WITH		Shared Dispositive Power				
			2,319,150				
9)	Aggregate A	mou	int Beneficially Owned by Each Reportin	ng Person			
	2,319,150						
10)							
	Not Applicable						
11)							
12)	5.26% 12) Type of Reporting Person						
	IV						

* This filing describes the reporting person's relationship with other persons, but the reporting person does not affirm the existence of a group.

1(a)	Name of Issuer:	Eiger BioPharmaceuticals, Inc.			
1(b)	Address of Issuer's Principal Executive Offices:	2155 Park Boulevard Palo Alto, CA 94306			
2(a)	Name of Person Filing:	 (a) Ameriprise Financial, Inc. ("AFI") (b) Columbia Management Investment Advisers, LLC ("CMIA") (c) Columbia Seligman Technology and Information Fund ("Fund") 			
2(b)	Address of Principal Business Office:	 (a) Ameriprise Financial, Inc. 145 Ameriprise Financial Center Minneapolis, MN 55474 (b) 290 Congress St. Boston, MA 02210 (c) 291 Congress Street Boston, MA 02211 			
2(c)	Citizenship:	(a) Delaware(b) Minnesota(c) Massachusetts			
2(d)	Title of Class of Securities:	Common Stock			
2(e)	Cusip Number:	28249U105			
3	Information if statement is filed pursuant to Rules 13d-1(b) or 13d-2(b): (a) Ameriprise Financial, Inc.				
A parent holding company in accordance with Rule 13d-1(b)(1)(ii)(G). (Note: See Item 7)					
	(b) Columbia Management Investment Advisers, LLC				

CMIA and AFI do not directly own any shares of Common Stock of the issuer. As the investment adviser to the Fund and various other unregistered and registered investment companies and other managed accounts, CMIA may be deemed to beneficially own the shares reported herein by the Fund.

An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
(c) Columbia Seligman Technology and Information Fund
An investment company in accordance with Rule 13d-1(b)(1)(ii)(D).

4

Incorporated by reference to Items (5)-(9) and (11) of the cover page pertaining to each reporting person.

Accordingly, the shares reported herein by CMIA include those shares separately reported herein by the Fund.

As the parent holding company of CMIA, AFI may be deemed to beneficially own the shares reported herein by CMIA. Accordingly, the shares reported herein by AFI include those shares separately reported herein by CMIA.

Each of AFI and CMIA, and the subsidiaries identified on the attached Exhibit I, disclaims beneficial ownership of any shares reported on this Schedule.

- 5 Ownership of 5% or Less of a Class: Not Applicable
- 6 Ownership of more than 5% on Behalf of Another Person:

To the knowledge of AFI, CMIA and the Fund, no other persons besides AFI, CMIA and the Fund and those persons for whose shares of common stock CMIA and AFI report beneficial ownership have the right to receive or the power to direct the receipt of dividends from or the proceeds from the sale of the securities of the issuer reported herein. As of December 31,2022, only the Fund owned more than 5% of the class of securities reported herein.

Any remaining shares reported herein by CMIA are held by various other funds or accounts managed by CMIA which each have the right to receive any dividends paid by the issuer and could terminate their respective investment advisory relationship with CMIA and then subsequently direct the use of proceeds from the sale of the common stock owned by such fund or account. To CMIA's knowledge, none of these other funds or accounts own more than 5% of the outstanding shares of the issuer as December 31,2022.

7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:

AFI: See Exhibit I

8 Identification and Classification of Members of the Group:

Not Applicable

9 Notice of Dissolution of Group:

Not Applicable

10 Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: January 10,2023

Ameriprise Financial, Inc.

By: /s/ Michael G. Clarke Name: Michael G. Clarke Title: Senior Vice President, Head of Global Operations

Columbia Management Investment Advisers, LLC

By: /s/ Michael G. Clarke Name: Michael G. Clarke Title: Senior Vice President, Head of Global Operations

Columbia Seligman Technology and Information Fund

By: /s/ Michael G. Clarke Name: Michael G. Clarke Title: Senior Vice President & Chief Financial Officer

Contact Information Mark D. Braley Vice President Head of Reporting and Data Management | Global Operations and Investor Services Telephone: (617) 747-0663

Exhibit Index

Exhibit I Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company.

Exhibit II Joint Filing Agreement

Exhibit I

to

Schedule 13G

Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940.

Exhibit II

to

Schedule 13G

Joint Filing Agreement

The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated January 10,2023 in connection with their beneficial ownership of Eiger BioPharmaceuticals, Inc.. Each of Columbia Seligman Technology and Information Fund and Columbia Management Investment Advisers, LLC authorizes Ameriprise Financial, Inc. to execute the Schedule 13G to which this Exhibit is attached and make any necessary amendments thereto.

Ameriprise Financial, Inc.

By: /s/ Michael G. Clarke

Name: Michael G. Clarke

Title: Senior Vice President, Head of Global Operations

Columbia Management Investment Advisers, LLC

By: /s/ Michael G. Clarke Name: Michael G. Clarke Title: Senior Vice President, Head of Global Operations

Columbia Seligman Technology and Information Fund

By: /s/ Michael G. Clarke

Name: Michael G. Clarke

Title: Senior Vice President & Chief Financial Officer